Form 4: Editas Medicine CEO Sells Shares to Cover Tax Obligations

Editas Medicine CEO Gilmore O'Neill sold 1,555 shares of common stock on September 4, 2024, to cover tax withholding obligations related to vesting restricted stock units.

Summary

• On September 4, 2024, Gilmore O'Neill, CEO of Editas Medicine, sold 1,555 shares of Editas Medicine common stock.
• The sale was executed at a weighted average price of $3.4247 per share.
• The shares were sold to cover tax withholding obligations resulting from the vesting of restricted stock units on September 2, 2024.
• Following the transaction, O'Neill directly owns 313,724 shares of Editas Medicine.
• The sale was conducted under a pre-arranged automatic sales instruction plan adopted on April 13, 2022.

Sentiment

Score: 5

Explanation: The document describes a routine transaction (stock sale for tax obligations) and doesn't contain information that would significantly sway investor sentiment positively or negatively.

Industry Context

Sales of shares to cover tax obligations upon vesting of restricted stock units are a common practice among corporate executives.

Comparison to Industry Standards

• Executive stock sales for tax purposes are a standard practice across publicly traded companies.
• Comparing O'Neill's transactions to those of CEOs at similar biotech firms like CRISPR Therapeutics or Intellia Therapeutics would provide a benchmark, but this data isn't available in this document.
• The use of a 10b5-1 plan is a common method to avoid accusations of insider trading, similar to practices at companies like Vertex Pharmaceuticals.

Key Dates